Movement Alert｜Pfizer Intraday Rise 3.03% in Regular Trading, RBC Upgrades Rating to Sector Perform

Market Focus06-11 22:19

On June 11, Pfizer rose 3.03% in regular trading, trading at $26.395/share, with trading value of $2.88 billion. The move was driven by RBC Capital Markets upgrading Pfizer from Underperform to Sector Perform while maintaining a $25 price target.

RBC noted that Pfizer's risk-reward profile has become more balanced following recent share price weakness, with valuations now closer to long-term averages and reduced downside concerns. The brokerage highlighted Pfizer's approximately 7% dividend yield as a key support factor, suggesting it may provide a floor for the stock as income-focused investors step in. Additionally, RBC pointed to two late-stage pipeline catalysts — sigvotatug vedotin in non-squamous non-small cell lung cancer with roughly $1.2 billion peak sales potential, and mevro in metastatic castration-resistant prostate cancer — both carrying approximately 60% probability of success, which could boost market expectations ahead of upcoming data readouts.

According to FactSet, analysts assign Pfizer an average overweight rating with a mean price target of $28.92.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172788975?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 22:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172788975","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Pfizer Intraday Rise 3.03% in Regular Trading, RBC Upgrades Rating to Sector Perform","media":"Market Focus","content":"<p><p>On June 11, Pfizer rose 3.03% in regular trading, trading at $26.395/share, with trading value of $2.88 billion. The move was driven by RBC Capital Markets upgrading Pfizer from Underperform to Sector Perform while maintaining a $25 price target.</p><p>RBC noted that Pfizer's risk-reward profile has become more balanced following recent share price weakness, with valuations now closer to long-term averages and reduced downside concerns. The brokerage highlighted Pfizer's approximately 7% dividend yield as a key support factor, suggesting it may provide a floor for the stock as income-focused investors step in. Additionally, RBC pointed to two late-stage pipeline catalysts — sigvotatug vedotin in non-squamous non-small cell lung cancer with roughly $1.2 billion peak sales potential, and mevro in metastatic castration-resistant prostate cancer — both carrying approximately 60% probability of success, which could boost market expectations ahead of upcoming data readouts.</p><p>According to FactSet, analysts assign Pfizer an average overweight rating with a mean price target of $28.92.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pfizer Intraday Rise 3.03% in Regular Trading, RBC Upgrades Rating to Sector Perform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pfizer Intraday Rise 3.03% in Regular Trading, RBC Upgrades Rating to Sector Perform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-11 22:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, Pfizer rose 3.03% in regular trading, trading at $26.395/share, with trading value of $2.88 billion. The move was driven by RBC Capital Markets upgrading Pfizer from Underperform to Sector Perform while maintaining a $25 price target.</p><p>RBC noted that Pfizer's risk-reward profile has become more balanced following recent share price weakness, with valuations now closer to long-term averages and reduced downside concerns. The brokerage highlighted Pfizer's approximately 7% dividend yield as a key support factor, suggesting it may provide a floor for the stock as income-focused investors step in. Additionally, RBC pointed to two late-stage pipeline catalysts — sigvotatug vedotin in non-squamous non-small cell lung cancer with roughly $1.2 billion peak sales potential, and mevro in metastatic castration-resistant prostate cancer — both carrying approximately 60% probability of success, which could boost market expectations ahead of upcoming data readouts.</p><p>According to FactSet, analysts assign Pfizer an average overweight rating with a mean price target of $28.92.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"","article_id":"1172788975","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172788975","pubTimestamp":1781187546,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, Pfizer rose 3.03% in regular trading, trading at $26.395/share, with trading value of $2.88 billion. The move was driven by RBC Capital Markets upgrading Pfizer from Underperform to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"走势提示|辉瑞常规交易盘中涨3.03%RBC上调评级至行业表现","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"On June 11, Pfizer rose 3.03% in regular trading, trading at $26.395/share, with trading value of $2.88 billion. The move was driven by RBC Capital Markets upgrading Pfizer from Underperform to Sector Perform while maintaining a $25 price target.RBC noted that Pfizer's risk-reward profile has become more balanced following recent share price weakness, with valuations now closer to long-term averages and reduced downside concerns. The brokerage highlighted Pfizer's approximately 7% dividend yield as a key support factor, suggesting it may provide a floor for the stock as income-focused investors step in. Additionally, RBC pointed to two late-stage pipeline catalysts — sigvotatug vedotin in non-squamous non-small cell lung cancer with roughly $1.2 billion peak sales potential, and mevro in metastatic castration-resistant prostate cancer — both carrying approximately 60% probability of success, which could boost market expectations ahead of upcoming data readouts.According to FactSet, analysts assign Pfizer an average overweight rating with a mean price target of $28.92.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172788975","isCrawlerRequest":true}